Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

Zhongyu Zhu; Ponraj Prabakaran; Weizao Chen; Christopher C. Broder; Rui Gong; Dimiter S. Dimitrov

doi:10.1007/s12250-013-3313-x

Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

Zhongyu Zhu, Ponraj Prabakaran, Weizao Chen, Christopher C. Broder, Rui Gong^*, Dimiter S. Dimitrov

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

Original language	English
Pages (from-to)	71-80
Number of pages	10
Journal	Virologica Sinica
Volume	28
Issue number	2
DOIs	https://doi.org/10.1007/s12250-013-3313-x
State	Published - Apr 2013
Externally published	Yes

Keywords

Antibodies
Hendra virus
Nipah virus
SARS-CoV
Viruses

Access to Document

10.1007/s12250-013-3313-x

Cite this

@article{9d2c819319ee423fbefa3351ba2f4d3f,

title = "Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1",

abstract = "More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.",

keywords = "Antibodies, Hendra virus, Nipah virus, SARS-CoV, Viruses",

author = "Zhongyu Zhu and Ponraj Prabakaran and Weizao Chen and Broder, {Christopher C.} and Rui Gong and Dimitrov, {Dimiter S.}",

year = "2013",

month = apr,

doi = "10.1007/s12250-013-3313-x",

language = "English",

volume = "28",

pages = "71--80",

journal = "Virologica Sinica",

issn = "1674-0769",

number = "2",

}

TY - JOUR

T1 - Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

AU - Zhu, Zhongyu

AU - Prabakaran, Ponraj

AU - Chen, Weizao

AU - Broder, Christopher C.

AU - Gong, Rui

AU - Dimitrov, Dimiter S.

PY - 2013/4

Y1 - 2013/4

N2 - More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

AB - More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

KW - Antibodies

KW - Hendra virus

KW - Nipah virus

KW - SARS-CoV

KW - Viruses

UR - http://www.scopus.com/inward/record.url?scp=84879728492&partnerID=8YFLogxK

U2 - 10.1007/s12250-013-3313-x

DO - 10.1007/s12250-013-3313-x

M3 - Review article

C2 - 23575729

AN - SCOPUS:84879728492

SN - 1674-0769

VL - 28

SP - 71

EP - 80

JO - Virologica Sinica

JF - Virologica Sinica

IS - 2

ER -